




RealRate

PHARMACEUTICAL 2021

Madrigal Pharmaceuticals INC
Rank 254 of 394



The relative strengths and weaknesses of Madrigal Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Madrigal Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Madrigal Pharmaceuticals INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 104% points.

The company's Economic Capital Ratio, given in the ranking table, is 215%, being 41% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	285,163
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	46,557
Liabilities, Non-Current	468
Other Assets	785
Other Compr. Net Income	-169
Other Expenses	184,809
Other Liabilities	0
Other Net Income	4,329
Other Revenues	100
Property and Equipment	1,047
Research and Development	184,809
Selling, General and Administrative Expense	21,864

Output Variable	Value in 1000 USD
Assets	286,995
Liabilities	47,025
Expenses	391,482
Revenues	100
Stockholders Equity	239,970
Net Income	-387,053
Comprehensive Net Income	-387,138
BaseVar	365,050
ECR before Limited Liability	81%
Economic Capital Ratio	215%